Drug Discovery Tools for High-Content Analysis

Content

• 1. Overview
  • 1.1 Objectives of the Report
  • 1.2 Methodology
  • 1.3 Scope of the Report
  • 1.4 Executive Summary
• 2. Technologies and Product Offering for HCA
  • 2.1 Definition of HCA and Why it is so Attractive a Discipline
  • 2.2 Classes of Measurements Possible with HCA Approaches and Biologies Interrogated
  • 2.3 Instrumentation Platforms for HCA 17 2.4 Reagent and Assay Platforms for HCA
  • 2.5 Cell-based Screening Technologies in Drug Development
    • 2.5.1 Applications of Cell-based Assays
    • 2.5.2 Pharma Drug Discovery Paradigm and Compound Screening
    • 2.5.3 HCA in the Biopharmaceutical Industry
• 3. Market Analysis of the High-Content Tools Space
  • 3.1 HCA Market Size and Growth
  • 3.2 Market Survey to Assess Qualitative and Quantitative Parameters of the HCA Space
  • 3.3 Experimental and Research Trends in HCA
  • 3.4 Challenges and Market Drivers in HCA
    • 3.4.1 Barriers to HCA 39 3.4.2 Drivers of HCA
  • 3.5 HCA in Combination with RNAi
  • 3.6 Market Landscape of Instrumentation for HCA
  • 3.7 Reagents and Assays USAge in HCA
  • 3.8 Trends in HCA Assays/Reagents Space-Major Product Vendors
  • 3.9 Emerging Market Trends in HCA
  • 3.10 Market Forecasts for the HCA Space
  • 3.11 Use of HCS in Pharmaceutical Companies
  • 3.12 Qualitative Opportunities and Challenges for Market Adoption
• 4. Strategic Analysis of the High-Content Tools Space
  • 4.1 HCA Market Structure
  • 4.2 Description of the Drug Discovery Marketplace and Definition of the Field
  • 4.3 Key Market Drivers and Challenges in the HCA Space
  • 4.4 Consolidated Picture of the HCA Marketplace
  • 4.5 HCA Market Sectors and Growth Rate
  • 4.6 Vendors of HCA Technology
• 5. HCA Technology Platforms
  • 5.1 Methods of Digital Imaging
  • 5.2 Fluorescence Microscopy
  • 5.3 Major HCA Instrumentation
  • 5.4 HCA Reagents
  • 5.5 Imaging Software
  • 5.6 Image Analysis Algorithms
  • 5.7 Use of RNAi in HCA
  • 5.8 Industry Alliance to Leverage RNAi and HCA
  • 5.9 Emerging Trends in HCA Technology Platforms
• 6. HCA in Drug Selection and Screening
  • 6.1 Stem Cells Used as a Drug Discovery Tool
  • 6.2 Drug Discovery Companies Marketing Cell-based Assays
• 7. Company Profiles and Glossary of Terms in HCA
  • 7.1 Acumen Pharmaceuticals, Inc.
  • 7.2 Applied Biosystems
  • 7.3 Becton, Dickinson and Company
  • 7.4 Beckman Coulter, Inc.
  • 7.5 Blueshift Biotechnologies, Inc.
  • 7.6 Caden Biosciences, Inc.
  • 7.7 Cellomics, Inc.
  • 7.8 Cellumen, Inc.
  • 7.9 Cenix BioScience
  • 7.10 Cyntellect
  • 7.11 Definiens
  • 7.12 DiscoveRx
  • 7.13 Euroscreen
  • 7.14 Evotec Technologies
  • 7.15 Fisher BioImage
  • 7.16 General Electric
  • 7.17 Guava Technologies, Inc.
  • 7.18 Millipore
  • 7.19 Molecular Devices Corporation
  • 7.20 NIH Chemical Genomics Center
  • 7.21 PerkinElmer
  • 7.22 Spotfire
  • 7.23 Translational Genomics Research Institute
  • 7.24 Vala Sciences, Inc.
• 8. Glossary of Terms in the HCA Space
• List Of Figures
  • Figure 2.1: Scope of Biological Parameters Addressed via a Typical HCA Experiment
  • Figure 2.2: Classes of Assays in Life Science Research and Drug Discovery Illustrating the Relationship between Cell-based Assays and HCA
  • Figure 2.3: New Paradigm of Drug Discovery and Development Illustrating the Central and Essential Role of Screening
  • Figure 2.4: Cumulative and New Drug Targets
  • Figure 3.1: Breakout of Market Survey Respondents by Geographical Location
  • Figure 3.2: Breakout of Market Survey Respondents by Affiliation-Academic, Commercial, Vendor
  • Figure 3.3: Segmentation of Respondent Pool based upon USAge of HCA in its Research Activities
  • Figure 3.4: Segmentation of the Survey Respondent Pool based upon the Length of Time they have been Using HCA in their Research Activities
  • Figure 3.5: Number of Parameters Studied Simultaneously in HCA Assays-Multivariate [Multi-Parameter] Analyses
  • Figure 3.6: Key Biological Processes Studied Utilizing HCA Tools
  • Figure 3.7: Breakout of HCA Assays Currently Performed or Expected to be Performed in the Future by Biological Pathway (or Target)
  • Figure 3.8: Breakout of HCA Experiments Performed Per Week (Distributed in our Respondent Pool) Across the Various Biological Pathways (and Targets)
  • Figure 3.9: Which of the Biologies (Pathways/Targets) Addressed Using HCA-based Approaches are Growing in Importance or Declining?
  • Figure 3.10: In Which Environment are HCA Assays Performed-Primary Screen, Secondary Screen, ADME/Tox Screen?
  • Figure 3.11: Key Challenges Faced by the Research Community in Their Practice of HCA
  • Figure 3.12: Various Drivers that are Leading the Research Community to Perform HCA
  • Figure 3.13: HCA Together with RNAi-Current and Future Experimental Formats
  • Figure 3.14: HCA Together with RNAi-Number of Experiments Performed Per Month by the Survey Respondent Pool
  • Figure 3.15: Growing and Steady USAge of the Various Formats where RNAi is coupled with HCA
  • Figure 3.16: Penetration of the Different HCA Instrumentation Platforms into the Marketplace
  • Figure 3.17: Instrumentation Platforms for HCA Ranked by Top Choice and Second Tier
  • Figure 3.18: HCA Instrumentation and where they lie on the Throughput Curve
  • Figure 3.19: Top Instrumentation Value Drivers in the HCA Space
  • Figure 3.20: Important Sub-Cellular Features Studied via HCA Approaches
  • Figure 3.21: Breakout of End-Point versus Kinetic Assays in the HCA Space
  • Figure 3.22: Types of Cellular Targets Studied Using HCA Approaches
  • Figure 3.23: Top-most Target Class Being Studied Utilizing HCA Approaches
  • Figure 3.24: Distribution of HCA Experiments across the Respondent Pool-Number of Experiments Performed Per Week
  • Figure 3.25: Average Reagent/Assay Costs Per HCA Experiment
  • Figure 3.26: Stratification of Reagent/Assay Suppliers into the HCA Space
  • Figure 3.27: Monthly Reagent/Assay Purchases for HCA by the End-User Community from the Various Vendors Offering Products into the Space
  • Figure 3.28: Growth or Decline in Importance of the Various HCA Vendors to the End-User Community
  • Figure 3.29: Percentage of HCA Experiments that Involve GFP across the Market Landscape
  • Figure 3.30: Breakout of HCA Reagents Marketplace: Home-Brew Versus Off-the-Shelf
  • Figure 3.31: Breakout of Spending into the Various Components of the HCA Discipline
  • Figure 3.32: Forecast Growth of the Total Screening Space-Broken-out by Primary Screening, Secondary Screening (Includes HCA as a Subset) and ADME/Tox
  • Figure 3.33: Forecast Growth of the Screening Space-Broken-out by Cell-based Assays and Biochemical Assays
  • Figure 4.1: Drug Discovery and Development Ensemble and the Position of the Various Segments of HCA in the Space
  • Figure 4.2: Relative Size and Position of the HCA Space in the Overall Scheme of the Life Science Tools Marketplace
  • Figure 5.1: HCA: Positional Biosensors Using Caspases and Monitoring the Translocation of a Tagged Protein from the Cytoplasm to the Nucleus
  • Figure 6.1: Druggability of the Various Target Classes: Breakout of the Drug Targets Today into their Constituent Classes
  • Figure 6.2: GPCR Assay Technologies
• List Of Tables
  • Table 2.1: Comparison of the Key Features of HCA and HCS
  • Table 2.2: Impact of HCA on Drug Discovery-Several Drivers are Addressed
  • Table 2.3: Biological Application Areas Associated with HCA
  • Table 2.4: Classes of Measurements and Targets Identified Using Phenotypic Screening (HCA)
  • Table 2.5: Classes of Cellular Measurements Possible with Fluorescent Protein Biosensors
  • Table 2.6: Multi-Parameter HCA Assays to Study Biological Systems in Life Science Research and Drug Discovery-Demonstrates the Breadth and Scalability of the HCA Approach
  • Table 2.7: Companies Offering Systems for High-Throughput Imaging
  • Table 2.8: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-I
  • Table 2.9: Comparison of the Major Instrumentation Platforms and their Associated Specifications for HCA-II
  • Table 2.10: Price Points and Target Markets of the Various HCA Instrument Platforms
  • Table 2.11: Companies Offering Flow Cytometry Products and Services
  • Table 2.12: Integrated Product Platforms Offered by the Different HCA Vendors
  • Table 2.13: Biologies interrogated by Cellomics HCA Assays
  • Table 2.14: Cellomics HitKit® HCA Assay/Reagent Kits and the Therapeutic Areas Where They Find Application
  • Table 2.15: Assay/Reagent Portfolio of Millipore Addressing HCA Applications
  • Table 2.16: Cell Lines for GPCR HCA that can be Deployed onto the BD Biosciences/Atto Pathway HT™ Instrument Platform
  • Table 2.17: Examples of High Content Screens
  • Table 3.1: What Fraction of HCA Assays are Cell-based Versus Biochemical-based
  • Table 4.1: Comparison of the Key Features of HCA and HCS
  • Table 4.2: Snapshot of the Various HCA Assays Demonstrating the Scalability of this Discipline
  • Table 5.1: Modes of Digital Imaging
  • Table 5.2: Modes of Fluorescence
  • Table 5.3: Major HCA Instrumentation
  • Table 5.4: Image Analysis Algorithms